Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 2;39(33):3671–3681. doi: 10.1200/JCO.21.00334

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 3. — Forest plot of OS by subgroup (ITT population). Note: The HR was not calculated for subgroups where the number of patients in either the nivolumab group or the GEM or PLD group was < 10 patients. HRs (95% CI) were estimated using the Cox proportional hazards model. The UICC TNM Classification version 7 was used. BRCA1, breast cancer susceptibility gene 1; BRCA2, breast cancer susceptibility gene 2; ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Obstetrics and Gynecology; GEM, gemcitabine; HR, hazard ratio; ITT, intention-to-treat; NA, not applicable; NLR, neutrophil to lymphocyte ratio; OS, overall survival; PD-L1, programmed cell death ligand-1; PLD, pegylated liposomal doxorubicin; TNM, TNM Classification of Malignant Tumors; UICC, Union for International Cancer Control.